Prophylactic intravesical instillation of epinephrine prevents cyclophosphamide-induced hemorrhagic cystitis in rats.
The objective of this study is to investigate the potential protective effects of intravesical instillation of epinephrine in cyclophosphamide-induced hemorrhagic cystitis. In an earlier study, we have shown that epinephrine promotes hemostasis on established hemorrhagic cystitis induced by cyclophosphamide. Female Sprague-Dawley rats were divided into seven groups as follows: group 1: positive control (150 mg/kg, cyclophosphamide, i.p.), group 2: negative control (10 microg/ml, epinephrine, intravesical), co-administration of cyclophosphamide (150 mg/kg, i.p.), group 3: saline (intravesical), groups 4-6: epinephrine (2.5, 5, and 10 mu g/ml, intravesical), and group 7: mesna (50 mg/kg, i.p.). Rats were sacrificed on 3 consecutive days and the urinary bladders were removed, weighed, and evaluated. The vesical vascular permeability was determined by wet bladder weight and Evan's blue dye absorbance. After 24 hours of cyclophosphamide administration, severe hemorrhagic cystitis was induced with marked edema, hemorrhage, and inflammation. In the epinephrine-treated groups, symptoms of hemorrhagic cystitis (such as edema, inflammation, and hemorrhage) were reduced significantly. Intravesical instillation of epinephrine prevents edema, hemorrhage, and inflammation in rats with cyclophosphamide-induced hemorrhagic cystitis.
Chow
Yung-Chiong
YC
Department and Institute of Physiology, School of Medicine, National Yang-Ming University, 155 Li-Nong Street, Section 2, Shih-Pai, Taipei, 11221 Taiwan, ROC.
Yang
Stone
S
Huang
Chun-Jen
CJ
Tzen
Chin-Yuan
CY
Su
Yu-Hsien
YH
Wang
Paulus S
PS
D000283:Administration, Intravesical; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000633:toxicity*; D002199:Capillary Permeability / Q000187:drug effects; D003520:Cyclophosphamide / Q000633:toxicity*; D003556:Cystitis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D004837:Epinephrine / Q000494:pharmacology*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D001743:Urinary Bladder / Q000473:pathology; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D018906:Antineoplastic Agents, Alkylating; D014662:Vasoconstrictor Agents; D003520:Cyclophosphamide; D004837:Epinephrine